Andrew R. Pachner

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

The triad of neurologic manifestations of Lyme disease

Andrew R. Pachner, Allen C. Steere · Neurology · 1985 · 582 citations

Medicine, Infectious Diseases, Neurology +14

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Facial paralysis in lyme disease

Jane Clark, Roy D. Carlson, Andrew R. Pachner et al. · The Laryngoscope · 1985 · 247 citations

Medicine, Neurology, Otolaryngology +10

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

Chris H. Polman, Antonio Bertolotto, Florian Deisenhammer et al. · The Lancet Neurology · 2010 · 199 citations

Life Sciences, Immunology, Neurology +15